Generic placeholder image

Current Cancer Drug Targets


ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Review Article

The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality

Author(s): Sebastiano Bordonaro, Massimiliano Berretta, Antonino Carmelo Tralongo, Silvia Clementi, Brigida Stanzione and Paolo Tralongo*

Volume 18, Issue 5, 2018

Page: [480 - 498] Pages: 19

DOI: 10.2174/1568009617666170209100322

Price: $65


Over the last 15 years, we have seen a huge expansion of the development of drugs directed against biomolecular targets within breast cancer cells. The over-expression of certain receptors (ER, PgR, HER-2, VEGF-R), as well as alteration of several intracellular signal transduction pathways (the PI3K-AKT-mTOR pathway, MEK-MAPK pathway, loss of PTEN, etc ...) has a great impact on the likelihood of recurrence and progression of the disease, influencing the natural history of breast cancer. The recent biomolecular classification of breast cancer (Luminal A / B, HER2- driven, Basal Like) allowed finally to identify specific treatments against molecular target to associate or not to traditional chemotherapy, and to use in relation to the prognosis of the disease. In the following paragraphs, we will set out the major targeted drug that have received indications in breast cancer, both in the localized and in advanced disease, referring to the specific target (hormonal receptors, HER2, VEGF, m-TOR, PARP etc ...).

Keywords: Breast, cancer, target, biomolecular, receptors, treatment, metastases.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy